IFN-λ4 is a novel type-III interferon with strong clinical significance in humans. Only a subset of individuals—up to 10% of Asians, 50% of Europeans, and 90% of Africans—carry the ΔG allele of a genetic variant rs368234815-TT/ΔG and are genetically able to produce IFN-λ4 protein. Carriers of the ΔG allele have impaired ability to clear infection with hepatitis C virus (HCV). IFN-λ4 is also predicted to exist and be functionally important in several nonhuman mammals. In this study, we present the first comparative analysis of 12 mammalian IFN-λ4 orthologs in a human hepatic cell line, HepG2, which supports signaling of the human IFN-λ4. We show that despite differences in protein sequences, functional properties of the recombinant human and nonhuman IFN-λ4 proteins are comparable—they are all expressed as predominantly cytoplasmic proteins that are biologically active for induction of interferon signaling.

We show that several IFN-λ4 orthologs can be detected by Western blotting, flow cytometry, and confocal imaging using a monoclonal antibody developed for the human IFN-λ4. Studies of IFN-λ4 in animals should help improve our understanding of the biology of this novel clinically important interferon in normal and disease conditions.

Introduction

Interferons (IFNs) are an essential part of the innate immune response, which is the first line of defense against pathogens. The induction of IFNs leads to activation of the JAK/STAT signaling pathway and expression of interferon-stimulated genes (ISGs) in the infected and the surrounding cells. This response can limit viral spread through mobilization of cellular defense mechanisms and elimination of infected cells (Parkin and Cohen 2001; Levy and others 2011).

IFNs are classified into three major groups—types I, II, and III—based on their receptor utilization. Type-I IFNs include a panel of IFN-α subtypes, IFN-β, IFN-ε, IFN-κ, and IFN-ω, all of which signal through a ubiquitous IFNAR receptor complex, consisting of the IFNAR1 and IFNAR2 receptors. IFN-γ, the only known type-II IFN, signals through its own receptor complex, IFNγR, consisting of the IFNγR1 and IFNγR2 receptors. Type-III IFNs (IFN-λ1-4) signal through the IFNLR receptor complex, which consists of the IFNL1 receptor specific to type-III IFNs, and the IL10R2 receptor shared by all type-III IFNs and the IL-10 family of cytokines. The signaling of type-III IFNs is restricted compared with other IFNs because expression of IFNL1 receptor is largely limited to epithelial cells, such as of the respiratory and gastrointestinal tract. IFN activity in these cells, which are commonly exposed to exogenous pathogens, is important for prevention of viral entry and dissemination.

A recently discovered type-III IFN, IFN-λ4 (Prokunina-Olsson and others 2013) reviewed in (O'Brien and others 2014), can be created only in the presence of the ΔG allele of a dinucleotide genetic variant rs368234815-TT/ΔG; this variant is polymorphic in humans, but only the ancestral ΔG allele seems to be present in nonhuman species. The human-specific TT allele, which eliminates IFN-λ4 protein by a frameshift in the first exon, appeared only 60,000 years ago (Key and others 2014). Apparently, this event was beneficial because it was favored by positive selection, which has resulted in a rapid increase of the TT allele frequency (or a rapid loss of the ΔG allele) in human populations (Key and others 2014).

Currently, up to 10% of Asians, 50% of Caucasians, and 90% of Africans carry at least one copy of the ΔG allele and thus can generate IFN-λ4. Carriers of the ΔG allele have impaired ability to clear hepatitis C virus (HCV) infection (Prokunina-Olsson and others 2013; Aka and others 2014). Chronic HCV infection eventually increases the risk of death due to liver failure and liver cancer, but this process takes decades, thus improvement of HCV clearance due to genetic inability to produce IFN-λ4 could not be the reason for the positive selection observed for the rs368234815-TT allele (Key and others 2014). The strength of this selection indicates...
that IFN-λ4 might have interfered with clearance of other more deadly pathogens, suggesting that elucidation of IFN-λ4 function could be important for understanding, prevention, and treatment of some existing and emerging infections.

So far, beyond HCV, the ΔG allele was also found to be associated with increased risk of cytomegalovirus infection in patients receiving solid organ transplants without antiviral prophylaxis (Manuel and others 2015); susceptibility to cytomegalovirus retinitis among HIV-infected individuals (Bibert and others 2014); decreased resistance to HIV infection (Real and others 2015); and unfavorable clinical and immunological status in HIV-infected individuals (Mackmach and others 2015). IFN-λ4 has been reported to induce antiviral response against coronaviruses (HCoV-229E and MERS-CoV), yellow fever virus, and dengue virus (Hamming and others 2013; Lu and others 2015); this list is likely not cross-react with the human IFN-λ3 protein. To reduce unspecific background in flow cytometry experiments, MAB-IFN-λ4 was buffer exchanged to PBS using Zeba 7k spin columns (Thermo Scientific), and for Western blot and confocal imaging, the MAB-IFN-λ4 was used without buffer exchange.

Expression constructs

The expression constructs (human IFN-λ4-Halo and control-Halo) based on the pFC14A vector (Promega) have previously been described (Prokunina-Olsson and others 2013). The control-Halo construct generates a Halo-tag protein with a size of 33 kDa, and the IFN-λ4-Halo construct generates the IFN-λ4-Halo protein (53 kDa) consisting of the IFN-λ4 protein (20 kDa) C-terminally fused with the Halo-tag protein (33 kDa). For the animal expression constructs, full-length open reading frames (ORFs) were predicted from DNA sequences available in the UCSC Genome browser based on similarity to human IFN-λ4 protein sequence.

We used information based on our earlier sequencing of the genomic DNA for chimpanzee IFN-λ4 (GenBank JX867772 and NM_001276259) and cynomolgus (crab-eating macaque; Genbank KC525948). Sequences for orangutan, marmoset, elephant, panda, megabat, cow, dog, and pig were only derived from the UCSC Genome browser and not validated by sequencing. Commercial genomic DNA sample for rhesus was obtained from Zyagen and used for Sanger sequencing of the predicted IFN-λ4 ORF.

Complete ORFs for IFN-λ4 orthologs (Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/jir) were ordered as custom synthetic genes subcloned in pDITBlue vector (IDT). The sequences were then PCR amplified and recloned into Halo-tag expression vector (Promega) to create constructs similar to the human IFN-λ4-Halo plasmid. The final constructs were fully sequenced for validation, propagated in E. coli, and purified with an endotoxin-free Maxi plasmid kit (Qiagen).

Materials and Methods

Cells

The human hepatoma cell line, HepG2 (ATCC HB-8065), was purchased from the American Tissue Culture Collection (ATCC) and maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS). The custom ISRE-Luc-HepG2 cell line stably expressing the luciferase reporter under control of the interferon-stimulated response element (ISRE) has previously been described (Prokunina-Olsson and others 2013); the cells were maintained in DMEM supplemented with 10% FBS and 1 μg/mL of puromycin (Gold Biotechnology).

Anti-IFN-λ4 antibodies

The mouse (MAB-IFN-λ4) and rabbit (RAB-IFN-λ4) monoclonal antibodies for IFN-λ4 have previously been described (Prokunina-Olsson and others 2013). MAB-IFN-λ4 (MABF227; Millipore) was raised against a synthetic peptide KALRDRYYEALSWGQRNCSPFRPRDSRPRPS corresponding to amino acids 44-74 and RAB-IFN-λ4 was raised against a synthetic peptide PGSSRKPQAKQRR HKPRADSPRC corresponding to amino acids 128-152 of the human IFN-λ4 protein (NP_001263183). The antibodies do not cross-react with the human IFN-λ3 protein. To reduce unspecific background in flow cytometry experiments, MAB-IFN-λ4 was buffer exchanged to PBS using Zeba 7k spin columns (Thermo Scientific), and for Western blot and confocal imaging, the MAB-IFN-λ4 was used without buffer exchange.

Expression constructs

The expression constructs (human IFN-λ4-Halo and control-Halo) based on the pFC14A vector (Promega) have previously been described (Prokunina-Olsson and others 2013). The control-Halo construct generates a Halo-tag protein with a size of 33 kDa, and the IFN-λ4-Halo construct generates the IFN-λ4-Halo protein (53 kDa) consisting of the IFN-λ4 protein (20 kDa) C-terminally fused with the Halo-tag protein (33 kDa). For the animal expression constructs, full-length open reading frames (ORFs) were predicted from DNA sequences available in the UCSC Genome browser based on similarity to human IFN-λ4 protein sequence.

We used information based on our earlier sequencing of the genomic DNA for chimpanzee IFN-λ4 (GenBank JX867772 and NM_001276259) and cynomolgus (crab-eating macaque; Genbank KC525948). Sequences for orangutan, marmoset, elephant, panda, megabat, cow, dog, and pig were only derived from the UCSC Genome browser and not validated by sequencing. Commercial genomic DNA sample for rhesus was obtained from Zyagen and used for Sanger sequencing of the predicted IFN-λ4 ORF.

Complete ORFs for IFN-λ4 orthologs (Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/jir) were ordered as custom synthetic genes subcloned in pDITBlue vector (IDT). The sequences were then PCR amplified and recloned into Halo-tag expression vector (Promega) to create constructs similar to the human IFN-λ4-Halo plasmid. The final constructs were fully sequenced for validation, propagated in E. coli, and purified with an endotoxin-free Maxi plasmid kit (Qiagen).

Transient transfection of HepG2 cells

HepG2 cells were reverse-transfected with corresponding constructs using Lipofectamine 3000 and Opti-MEM (Life Technologies).

Western blot

After transfection for 48 h in 6-well plates at a density of 350,000 cells/well, cells were lysed with 350 μL of RIPA buffer (Sigma) supplemented with Complete Ultra protease inhibitor (Roche). Equal amounts of proteins were resolved on 4%-12% Bis-Tris Bolt gels and transferred using iBlot2 (Life Technologies). Detection was done using primary antibodies MAB-IFN-λ4 (2 μg/mL), RAB-IFN-λ4 (0.5 μg/mL), and mouse α-Halo (1 μg/mL, G9211; Promega). Secondary HRP-tagged goat anti-rabbit (sc-2030) or goat antimouse (sc-2031) antibodies from Santa Cruz were used at a 1:10,000 dilution. Signals were detected with HyGlo Quick Spray (Denville Scientific) and viewed on the ChemiDoc Touch imager with ImageLab 5.2 software (BioRad).

Flow cytometry

For initial screening, transfections were done for 48 h in 6-well plates with 350,000 cells/well. Constructs, which
showed positive signals for MAB-IFN-λ4, were further evaluated by transfections in 12-well plates with 200,000 cells/well, in triplicates. Cells were harvested, fixed for 30 min at room temperature with 100 μL of cytix (BD Biosciences), and stained overnight in cytoperm (BD Biosciences) with 0.5 μg/mL of α-Halo, 1 μg/mL RAB-IFN-λ4, or 2 μg/mL of MAB-IFN-λ4. Secondary antibodies were donkey anti-mouse and donkey anti-rabbit Alexa Fluor 488 (1 μg/mL; Life Technologies). Cells were analyzed using multiparametric flow cytometry on a FACS Aria III (BD Biosciences) and FlowJo.10 software (Tree Star).

**Contofocal imaging**

Cells were transfected for 48 h on Nunc Lab-Tek II chamber slides (Thermo Scientific) at a concentration of 20,000 cells/chamber in 200 μL reaction volumes. Cells were fixed for 20 min in cytix (BD Biosciences), and then coincubated for 2 h with the MAB-IFN-λ4 (2 μg/mL) in cytoperm (BD Biosciences) and rabbit α-tubulin ab (1:500 dilution, ab-15246; Abcam). Samples were then incubated for 1 h at room temperature with donkey anti-mouse Alexa Fluor 594 and donkey anti-rabbit Alexa Fluor 488 secondary antibodies (1:1000 dilutions; Life Technologies). Alternatively, Halo-tag was detected with cell-permeant Halo-tag ligand (TMR red; Promega), which was added to live cells (1:2000 for 15 min), then the cells were washed and fixed for 20 min in cytix (BD Biosciences). Slides were covered with mounting media (Prolong Gold antifade reagent with DAPI). Immunofluorescent images were obtained with a confocal laser scanning microscope (LSM 700; Carl Zeiss) and analyzed using Zen software (Carl Zeiss).

**ISRE-luciferase assays**

Untransfected and transfected stable HepG2-ISRE-Luc cells were grown in 96-well plates at a concentration of 20,000 cells/well. The cells were lysed 48 h after plating and assayed for luciferase expression of the ISRE-Luc reporter using a GloMax luminometer (Promega). All transfections were done in 14 biological replicates, except for untransfected cells (6 biological replicates).

**Bioinformatic analysis**

IFN-λ4 protein sequences were analyzed with free online tools–Clustal W for sequence alignment and BoxShade for annotating amino acid similarities. Analysis of leader peptides was performed with online SignalP 4.1Server (Petersen and others 2011), and PSORT II analysis of nuclear localization signals and intracellular localization was performed with PSORT server (http://psort.hgc.jp/) (Nakai and Horton 1999). Statistical analysis and graphical presentation of results were done with GraphPad Prism 6 (GraphPad).

**Results and Discussion**

IFN-λ4 is a novel type-III IFN with moderate similarity to other type-III IFNs; it has 29% amino acid identity with IFN-λ3, the most related member of this family (Prokunina-Olsson and others 2013). The three other type-III IFNs (IFN-λ1, IFN-λ2, and IFN-λ3), which share high protein identity (81% between IFN-λ1 and IFN-λ2 and 96% between IFN-λ2 and IFN-λ3), were discovered in 2003 (Kotenko and others 2003; Sheppard and others 2003). All four type-III IFNs are encoded by a 55 Kb genomic cluster on the human chromosome19q13.2. Due to low sequence similarity between IFNL4 and the genes for other type-III IFNs, IFNλ4 could not be identified by a homology search. The reference human genome sequence has the rs368234815-TT allele, which does not support the IFN-λ4 ORF, thus the existence of IFN-λ4 was not predicted. IFN-λ4 was identified by direct cloning and annotation of sequences discovered through RNA sequencing of human hepatocytes treated with PolyI:C to mimic viral infection (Prokunina-Olsson and others 2013).

Once the protein sequence of human IFN-λ4 was known, it was used to search for IFN-λ4 orthologs in all ~100 vertebrate species with genomic information available through the UCSC Genome browser. Complete ORFs encoding IFN-λ4 proteins were found in several mammalian species, but not in nonmammals (Key and others 2014). The regions corresponding to IFN-λ4 could not be found in the mouse and rat genomes, although orthologs for IFN-λ2 and IFN-λ3 are present in these species. Now, we generated expression constructs for 11 IFN-λ4 orthologs (Fig. 1 and Supplementary Table S1) and tested their functionality in a human hepatoma cell line, HepG2, in comparison with human IFN-λ4.

We used the human cell line, HepG2, because it has all necessary components for type-III IFN signaling and was used to characterize human IFN-λ4. We recognize that a human cell line may not be optimal for all IFN-λ4 orthologs because the human receptors (IFNLR1 and IL10R2) and other signaling components may not work efficiently with nonhuman IFN-λ4s. However, our aim was to perform initial comparative characterization of IFN-λ4 orthologs in the same established experimental system. Additional studies on IFN-λ4 orthologs should be performed in experimental systems relevant for species of interest.

Protein sequence alignment of IFN-λ4 orthologs showed high similarity between primates, while more diversity was observed among nonprimate species (Fig. 1). All orthologs were predicted to have a leader peptide, with a cleavage site located between amino acids 22 and 23 in most cases and between 21 and 22 or 23 and 24 in some cases. Interestingly, the lowest leader peptide prediction score was for human IFN-λ4 (0.56), followed by marmoset (0.67); all other orthologs had higher prediction scores (0.77–0.87) (Table 1). However, a swap of leader peptides between the poorly secreted IFN-λ4 and highly secreted IFN-λ3 did not affect the secretion of IFN-λ4 (Hamming and others 2013), suggesting that the predicted strength of the leader peptide might not be relevant for IFN-λ4 secretion. The most diverse area in IFN-λ4 is the sequence immediately after the predicted leader peptide—the 7 amino acid fragment was missing in all primates and this sequence was different in all nonprimates (Fig. 1). This fragment did not seem to affect the leader peptide prediction scores and its functional significance is unclear.

Despite being only poorly secreted, human IFN-λ4 can efficiently activate IFN signaling (Prokunina-Olsson and others 2013; Onabajo and others 2015). We evaluated biological activity of the IFN-λ4 orthologs after transient expression in HepG2 cells stably expressing an interferon-stimulated response element (ISRE) coupled with luciferase reporter (ISRE-Luc); this system was previously used
to characterize human IFN-λ4. We observed differential biological activity of the IFN-λ4 orthologs: compared with human IFN-λ4, proteins from chimpanzee, orangutan, marmoset, and cynomolgus showed similar levels of biological activity (ISRE-Luc activation), while the dog protein showed significantly higher activity (by 40%). Orthologs from rhesus, panda, and elephant were significantly less active (25% compared with the human IFN-λ4, Fig. 2). Biological activities of the IFN-λ4 orthologs measured in this experiment are likely to be affected by differential affinity of these proteins to human receptors and do not represent quantitative comparisons. However, the fact that all of the IFN-λ4 orthologs were able to activate ISRE-Luc reporter above the background level (control-Halo) indicates that these proteins are biologically active as IFNs, even in human cells.

### Table 1. Prediction of Leader Peptides in IFN-λ4 Orthologs Based on SignalP Analysis

| IFN-λ4 orthologs | Leader peptide | Score | Cut site | Position, aa |
|------------------|----------------|-------|----------|-------------|
| Human            | Yes            | 0.56  | IAA-AP   | 22–23       |
| Chimpanzee       | Yes            | 0.86  | VAA-AP   | 22–23       |
| Orangutan        | Yes            | 0.87  | VAA-AP   | 22–23       |
| Rhesus           | Yes            | 0.85  | VTA-AP   | 22–23       |
| Marmoset         | Yes            | 0.67  | GAA-AP   | 22–23       |
| Cynomolgus       | Yes            | 0.85  | VTA-AP   | 22–23       |
| Dog              | Yes            | 0.82  | GDA-AE   | 22–23       |
| Panda            | Yes            | 0.79  | GEA-AD   | 22–23       |
| Elephant         | Yes            | 0.84  | VAA-EP   | 23–24       |
| Pig              | Yes            | 0.86  | VFA-LD   | 22–23       |
| Megabat          | Yes            | 0.77  | VAA-DH   | 21–22       |
| Cow              | Yes            | 0.77  | VAA-NP   | 23–24       |

**FIG. 1.** Multiple alignment of IFN-λ4 orthologs. ClustalW sequence alignment for IFN-λ4 orthologs. Shaded in black—identical amino acids, in gray—similar amino acids. The locations of synthetic peptides used to generate monoclonal antibodies, MAB-IFN-λ4 and RAB-IFN-λ4, are indicated.

**FIG. 2.** Analysis of biological activity of IFN-λ4 orthologs. Results of transient transfections of expression constructs producing IFN-λ4 orthologs in the HepG2 cell line stably expressing the ISRE-Luc reporter. The results are normalized to human IFN-λ4 and represent mean values of 14 biological replicates for all samples, except for untransfected cells (n = 6), all with standard errors. * = P < 0.001 compared with activity of human IFN-λ4. All orthologs showed significantly higher biological activity compared with control-Halo (background).
Because all of the IFN-λ4 orthologs are predicted to have leader peptides and showed biological activity for induction of IFN signaling, which is typical for exogenously acting IFNs, it is likely that at least a portion of these proteins is secreted. At the same time, if these orthologs behave like the human IFN-λ4, they will also be retained in the cytoplasm. To test this, we evaluated protein expression and cellular localization of all orthologs transiently expressed in HepG2 cells. Western blot analysis of protein lysates (Fig. 3), flow cytometry analysis (Supplementary Fig. S1), and confocal imaging (Supplementary Fig. S2) confirmed that all IFN-λ4 orthologs are detectable by an antibody or a fluorescent ligand for the Halo-tag, which is present on all these proteins. Confocal imaging showed that in most cases, IFN-λ4 was expressed as a cytoplasmic protein, although, in some cases, it was also detected in the nucleus (such as in dog and panda, Supplementary Fig. S2). PSORT analysis (Nakai and Horton 1999) identified nuclear localization signals within IFN-λ4, and some of the orthologs were predicted to be nuclear proteins (Supplementary Table S2); however, there was no correlation between these predictions and intracellular localization observed by confocal imaging. It is possible that nuclear localization of IFN-λ4 might be an alternative option utilized in some specific conditions. Cytoplasmic–nuclear shuttling has been reported for some factors involved in immune response (Jans and Hassan 1998), including IFN-γ (Subramaniam and others 1999) and IRF3 (Kumar and others 2000), and the possible functional effects associated with nuclear translocation of IFN-λ4 should be further explored in relevant experimental models.

Next, we tested the possibility of detection of IFN-λ4 orthologs with two custom monoclonal antibodies generated against nonoverlapping peptides within the N and C-terminal parts of the human IFN-λ4 protein. In Western blot analysis (Fig. 3), flow cytometry (Fig. 4 and Supplementary Figs S1 and S3), and confocal imaging (Fig. 5), the mouse monoclonal antibody (MAB-IFN-λ4) recognized IFN-λ4 from the human, chimpanzee, orangutan, rhesus, marmoset, cynomolgus (all the primates in the panel), and elephant. The results were similar for orthologs that were detectable both by Halo-tag and MAB-IFN-λ4. The rabbit monoclonal antibody (RAB-IFN-λ4) recognized only the human IFN-λ4. This is likely because the area that can be recognized by MAB-IFN-λ4 is more conserved between species compared with the area that can be recognized by the RAB-IFN-λ4 (Fig. 1).

**FIG. 3.** Western blots of IFN-λ4 orthologs. Western blot analysis of equal amounts of whole-cell protein lysates of HepG2 cells transiently transfected with expression constructs generating IFN-λ4 orthologs. (A) Positive control—detection by the α-Halo antibody for the C-terminal Halo-tag present in all IFN-λ4-Halo proteins. Halo protein alone produces a band of 33 kDa, IFN-λ4-Halo proteins produce bands of 55 kDa. (B) MAB-IFN-λ4 detects IFN-λ4-Halo proteins (55 kDa) produced only by a subset of orthologs. (C) RAB-IFN-λ4 detects only human IFN-λ4.

**FIG. 4.** Flow cytometry of IFN-λ4 orthologs. (A) Representative images of flow cytometry for IFN-λ4 transiently overexpressed in HepG2 cells and stained with MAB-IFN-λ4. Full results are shown as Supplementary Fig. S3. (B) Graphical representation of A. All results represent triplicates, except for negative results (dog, panda, pig, bat, and cow), which were done in single replicates. Results represent mean values with standard deviations when appropriate.
Further genomic studies may help to identify IFN-λ4 orthologs in other relevant species. The success and accuracy of these predictions rely on the quality and completion of available genomic sequencing and additional targeted DNA sequencing is often needed to validate the existing sequences and close the gaps. Detailed analysis of functional properties of IFN-λ4 orthologs in relation to differences in protein sequences could provide additional information on its biology.

In conclusion, the importance of IFN-λ4 in different aspects of antiviral response can be implied based on the conservation of its sequence and biological activity in mammals. However, it remains largely unknown what factors induce endogenous IFN-λ4 expression in different conditions and why elimination of IFN-λ4 was a beneficial event in humans strongly supported by positive selection. Answers to these questions might be relevant for dealing with existing and emerging infections across species. Viral infections have been directly responsible for some of the most dramatic and deadly disease pandemics in human history and many of these infections, including the recent Ebola outbreak, are of zoonotic origin (Jones and others 2008). There are also indirect devastating effects of these infections through the loss of livestock and wildlife, causing food shortages and financial distress (Frolich and others 2002; Thumbi and others 2015). Some animals and corresponding derived cell lines are used for studies of human infections and vaccine development (Meurens and others 2012; Gerds and others 2015). Thus, our findings and research tools might help to identify factors that trigger IFN-λ4 expression and explore the spectrum of its biological effects in different conditions.

Acknowledgment

The work has been supported by the Intramural Research Program (IRP) of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US.

Author Disclosure Statement

L.P.-O. is a coinventor on a patent application related to IFN-λ4 filed by the NCI/NIH.

References

Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O’Brien TR. 2014. Association of the IFNL4-DeltaG Allele with impaired spontaneous clearance of Hepatitis C Virus. J Infect Dis 209(3):350–354.

Bibert S, Wojtowicz A, Taffe P, Manuel O, Bernasconi E, Furrer H, Gunthard HF, Hoffmann M, Kaiser L, Osthoff M, Cavassini M, Bochud PY, Swiss HIVCS. 2014. The IFNL3/4 DeltaG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 28(13):1885–1889.

Frolich K, Thiede S, Kozikowski T, Jakob W. 2002. A review of mutual transmission of important infectious diseases between livestock and wildlife in Europe. Ann N Y Acad Sci 969:4–13.

Gerds V, Wilson HL, Meurens F, van Drunen Littel-van den Hurk S, Wilson D, Walker S, Wheler C, Townsend H, Potter AA. 2015. Large animal models for vaccine development and testing. ILAR J 56(1):53–62.

Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H, Siupka P, Pietschmann T, Thiel V, Hartmann R. 2013. Interferon lambda 4 signals via the IFN-lambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 32(23):3055–3065.

Jans DA, Hassan G. 1998. Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling? Bioessays 20(5):400–411.

Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. 2008. Global trends in emerging infectious diseases. Nature 451(7181):990–993.

Key FM, Peter B, Dennis MY, Huerta-Sanchez E, Tang W, Prokunina-Olsson L, Nielsen R, Andres AM. 2014. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet 10(10):e1004681.

Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69–77.
Kumar KP, McBride KM, Weaver BK, Dingwall C, Reich NC. 2000. Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1. Mol Cell Biol 20(11):4159–4168.

Levy DE, Marie JJ, Durbin JE. 2011. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1(6):476–486.

Lu YF, Goldstein DB, Urban TJ, Bradrick SS. 2015. Interferon-lambda4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology 476: 334–340.

Machmach K, Abad-Molina C, Romero-Sanchez MC, Dominguez-Molina B, Moyano M, Rodriguez MM, Rafai-El-Idrissi Benhnia M, Jimenez-Meijas ME, Vidal F, Munoz-Fernandez MA, Genebat M, Viciana P, Gonzalez-Escritano MF, Leal M, Ruiz-Mateos E. 2015. IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. Clin Microbiol Infect 21(3):289 e1–e4.

Manuel O, Wojtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, Steiger J, Stern M, Egli A, Garzoni A, Binet I, Weisser M, Berger C, Cusini A, Meylan P, Pascual M, Bochud PY, Swiss Transplant Cohort S, Swiss Transplant Cohort Study S. 2015. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 211(6):906–914.

Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdts V. 2012. The pig: a model for human infectious diseases. Trends Microbiol 20(1):50–57.

Nakai K, Horton P. 1999. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci 24(1):34–36.

O’Brien TR, Prokunina-Olsson L, Donnelly RP. 2014. IFN-lambda4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res 34(11):829–838.

Onabajo OO, Porter-Gill P, Paquin A, Rao N, Liu L, Tang W, Brand N, Prokunina-Olsson L. 2015. Expression of interferon lambda 4 is associated with reduced proliferation and increased cell death in human hepatic cells. J Interferon Cytokine Res doi: 10.1089/jir.2014.0161

Parkin J, Cohen B. 2001. An overview of the immune system. Lancet 357(9270):1777–1789.

Petersen TN, Brunak S, von Heijne G, Nielsen H. 2011. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 8(10):785–786.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Muny A, Koehler I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O’Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2):164–171.

Real LM, Herrero R, Rivero-Juarez A, Camacho A, Macias J, Vic S, Viedma S, Soriano V, Guardiola J, Fliba J, Rivero A, Pineda JA, Caruz A. 2015. IFN-4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. AIDS 29. doi: 10.1097/qad.0000000000000773

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrandr C, Dong D, Shin J, Presnll S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McNight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63–68.

Subramaniam PS, Mujtaba MG, Paddy MR, Johnson HM. 1999. The carboxyl terminus of interferon-gamma contains a functional polybasic nuclear localization sequence. J Biol Chem 274(1):403–407.

Thumbi SM, Njenga MK, Marsh TL, Noh S, Otiang E, Munyua P, Ochieng L, Ogola E, Yoder J, Audi A, Montgomery JM, Bigogo G, Breiman RF, Palmer GH, McElwain TF. 2015. Linking human health and livestock health: a “one-health” platform for integrated analysis of human health, livestock health, and economic welfare in livestock dependent communities. PLoS One 10(3):e0120761.

Address correspondence to:
Dr. Ludmila Prokunina-Olsson
Laboratory of Translational Genomics
Division of Cancer Epidemiology and Genetics
National Cancer Institute
National Institutes of Health
8717 Grovemont Circle
Bethesda, MD 20892-4605
E-mail: prokuninal@mail.nih.gov

Received 28 May 2015/Accepted 13 July 2015